Study on Limiting Treatment Time with Acalabrutinib and Obinutuzumab for People with CLL or SLL

Inclusion Criteria

• Must be 18 years or older.
• Have not received previous treatment for CLL or SLL.
• Have a confirmed diagnosis of CLL or SLL and need treatment according to specific guidelines.
• Be in good general health with a performance status score of 0, 1, or 2.
• Have adequate organ and bone marrow function, as shown by specific blood test results.
• Women of childbearing potential must agree to use effective birth control during the study and for 18 months after the last dose.
• Men must agree to use effective birth control during the study and for 6 months after the last dose.

Exclusion Criteria

• Have received any prior treatment specifically for CLL.
• Have taken any investigational drug within 30 days before starting the study.
• Have a history of other cancers that could interfere with the study, except for certain skin cancers or other cancers treated successfully over 3 years ago.
• Have CLL that has transformed into a more aggressive form of lymphoma.
• Have certain genetic mutations or deletions in the cancer cells.
• Have a history of central nervous system lymphoma.
• Have known allergies to the study drugs.
• Have active bleeding or a bleeding disorder.
• Have severe or uncontrolled medical conditions that could affect participation.
• Have active infections or have had a major infection requiring hospitalization recently.
• Require the use of certain medications that could interfere with the study.
• Have uncontrolled autoimmune conditions.
• Have a gastrointestinal ulcer diagnosed recently.
• Have an active HIV infection.
• Have received live vaccines recently.
• Are pregnant, breastfeeding, or planning to become pregnant during the study.
• Have had major surgery recently and not fully recovered.
• Have conditions that prevent taking oral medication.
• Are participating in another clinical trial.
• Are unable or unwilling to follow study procedures and evaluations.